ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like How This New Jersey Biotech is Taking on Amgen March 23, 2017 Jazz Pharma Bets $175 Million on This Massachusetts Biotech's Antibody-Drug Program August 28, 2017 4 Biotechs Facing Do-or-Die Catalysts in December December 5, 2017
